公开(公告)号：EP3875475A1

公开(公告)日：2021-09-08

申请号：EP19898340.5

申请日：2019-12-20

申请人： Jiangsu Hengrui Medicine Co., Ltd. ,  Shanghai Hengrui Pharmaceutical Co., Ltd. ,  Shanghai Shengdi Pharmaceutical Co., Ltd

发明人： CHEN, Lei ,  HU, Qiyue ,  GE, Hu ,  LIN, Yuan ,  WANG, Hongwei ,  OU, Yangchao ,  KONG, Xianglin ,  LIAO, Cheng ,  ZHANG, Lianshan

IPC分类号： C07K14/55 ,  C07K17/08 ,  C07K19/00 ,  C12N15/26 ,  C12N15/63 ,  C12P21/02 ,  A61K38/20 ,  A61K47/60 ,  A61K47/62 ,  A61K47/68 ,  A61P35/00 ,  A61P37/00

摘要： Provided is a human interleukin-2 (IL-2) variant having one or more amino acid mutations or a derivative thereof. The IL-2 variant or derivative thereof has increased stability compared to wild-type IL-2 and improved properties as an immunotherapeutic agent. Also disclosed are an immunoconjugate and a pharmaceutical composition which comprise the human IL-2 variant or derivative thereof, a polynucleotide molecule encoding same, a vector, a host cell and a preparation method therefor, as well as the pharmaceutical uses of the IL-2 variant or derivative thereof and the immunoconjugate or pharmaceutical composition comprising the L-2 variant or derivative thereof.